Home > Expanded Access > An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Genentech, Inc.

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure ...

Official Title: 
An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.
Brief Summary: 
This is an open-label, multicenter, single-arm, expanded access program (EAP) designed to provide atezolizumab access to participants with locally advanced or metastatic urothelial carcinoma that has progressed on, or is intolerant to, a platinum-containing chemotherapy regimen.
Approved for marketing
Urothelial Carcinoma

Drug: Atezolizumab [TECENTRIQ]
Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.

Eligibility Criteria: 

Inclusion Criteria:

- Able to comply with the study protocol, in the investigator's judgment

- Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra)

- Disease progression during or following treatment with at least one platinum-containing regimen (e.g., gemcitabine and cisplatin [GC], methotrexate, vinblastine, doxorubicin, and cisplatin [MVAC], carboplatin and gemcitabine [CarboGem], etc.) for inoperable locally advanced or metastatic urothelial carcinoma or disease recurrence

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

- Life expectancy >/= 12 weeks

- Adequate hematologic and end-organ function, defined by laboratory results obtained within 14 days prior to the first study treatment

- For women who are not postmenopausal (>/= 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined non-hormonal contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 90 days after the last dose of study drug

Exclusion Criteria:

- Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment

- Treatment with chemotherapy 14 days prior to enrollment; however, participants may be re-screened after the 14-day washout period

- Treatment with radiotherapy 7 days prior to enrollment; however, participants may be re-screened after the 14-day washout period

- Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases

- Pregnant or lactating, or intending to become pregnant during the study

- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to randomization, unstable arrhythmias, or unstable angina

- Severe infections within 4 weeks prior to enrollment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

- Received therapeutic oral or intravenous (IV) antibiotics within 14 days prior to enrollment; however, participants may be re-screened after the 14-day washout period

- Major surgical procedure within 4 weeks prior to enrollment or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of disease or a condition that contraindicates the use of the investigational drug or renders the participant at high risk for treatment complications

- Participants with active hepatitis B

- Active tuberculosis

- Administration of a live, attenuated vaccine within 4 weeks prior to enrollment or anticipation that such a live, attenuated vaccine will be required during the study

- Treatment with systemic immunostimulatory agents (including, but not limited to, interferons or IL-2) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to enrollment

- Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including, but not limited to, prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to enrollment or anticipated requirement for systemic immunosuppressive medications during the trial

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Countries: 
United States
Locations: 

Scottsdale, Arizona, 85258

Tucson, Arizona, 85710

Duarte, California, 91010

Oakland, California, 94611

Stanford, California, 94305

Denver, Colorado, 80218

New Haven, Connecticut, 06520

West Hartford, Connecticut, 06119

Miami Beach, Florida, 33140

Tampa, Florida, 33612

Harvey, Illinois, 60426

Springfield, Illinois, 62794-9677

Goshen, Indiana, 46526

Indianapolis, Indiana, 46237

Sioux City, Iowa, 51101

Louisville, Kentucky, 40202

New Orleans, Louisiana, 70112

Boston, Massachusetts, 02114

Boston, Massachusetts, 02115

Boston, Massachusetts, 02215

Ann Arbor, Michigan, 48106

Detroit, Michigan, 48202

St. Cloud, Minnesota, 56303

Jackson, Mississippi, 39202

Saint Louis, Missouri, 63110

Albuquerque, New Mexico, 87131-0001

Abany, New York, 12208

New York, New York, 10016

Rochester, New York, 14642

Columbus, Ohio, 43210

Eugene, Oregon, 97401-8122

Easton, Pennsylvania, 18045

Philadelphia, Pennsylvania, 19107

Pittsburgh, Pennsylvania, 15212

Charleston, South Carolina, 29425

Houston, Texas, 77030

San Antonio, Texas, 78229

Charlottesville, Virginia, 22908

Norfolk, Virginia, 23502

Spokane, Washington, 99208

Clinical Trials
Study Director
Genentech, Inc.

Genentech, Inc.
EA Number: 
MeSH Terms: 
Carcinoma, Carcinoma, Transitional Cell, Atezolizumab, Antibodies, Monoclonal
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.